ETI-204

BIOLOGICAL4 trials

Sponsors

Elusys Therapeutics

Conditions

Inhalational Anthrax

Phase 1

Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

CompletedNCT01929226

Elusys TherapeuticsInhalational Anthrax

Start: 2013-07-09End: 2013-11-29Updated: 2019-04-08

Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers

CompletedNCT01932437

Elusys TherapeuticsInhalational Anthrax

Start: 2013-07-26End: 2014-07-03Updated: 2019-05-06

Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

CompletedNCT01932242

Elusys TherapeuticsInhalational Anthrax

Start: 2013-07-23End: 2014-04-19Updated: 2019-05-14

Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

CompletedNCT01952444

Elusys TherapeuticsInhalational Anthrax

Start: 2013-10-29End: 2014-04-09Updated: 2019-04-16

Related Papers

Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies

Clinical Therapeutics2016-08-3021 citations